Evidence map›Paper›PMID 41304909›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

Bromocriptine, Selegiline and Amantadine in the Treatment of Depression-A Systematic Review.

Rafał Bieś, Marek Krzystanek, Michał Górski, Agnieszka Koźmin-Burzyńska, Anna Warchala, Beata Trędzbor, Ewa Martyniak, Joanna Fojcik

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rafał BieśDepartment and Clinic of Psychiatric Rehabilitation, Doctoral School, Faculty of Medical Sciences, Medical University of Silesia in Katowice, 40-635 Katowice, Poland.ORCID 0009-0005-0583-6661
Marek KrzystanekDepartment and Clinic of Psychiatric Rehabilitation, Faculty of Medical Sciences, Medical University of Silesia in Katowice, 40-635 Katowice, Poland.
Michał GórskiDepartment of Chronic Diseases and Civilization-Related Hazards, Faculty of Public Health in Bytom, Medical University of Silesia in Katowice, 40-055 Katowice, Poland.ORCID 0000-0002-0654-3765
Agnieszka Koźmin-BurzyńskaDepartment of Psychiatry, Department of Neurology, Faculty of Health Sciences in Katowice, Medical University of Silesia in Katowice, 40-635 Katowice, Poland.ORCID 0009-0002-3813-1527
Anna WarchalaDepartment and Clinic of Psychiatric Rehabilitation, Faculty of Medical Sciences, Medical University of Silesia in Katowice, 40-635 Katowice, Poland.ORCID 0000-0001-8676-3356
Beata TrędzborDepartment and Clinic of Psychiatric Rehabilitation, Faculty of Medical Sciences, Medical University of Silesia in Katowice, 40-635 Katowice, Poland.
Ewa MartyniakDepartment and Clinic of Psychiatric Rehabilitation, Faculty of Medical Sciences, Medical University of Silesia in Katowice, 40-635 Katowice, Poland.
Joanna FojcikDepartment of Psychiatry, Department of Neurology, Faculty of Health Sciences in Katowice, Medical University of Silesia in Katowice, 40-635 Katowice, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

amantadineanhedoniabromocriptinedepressiondopamine agonistsdopaminergic antidepressantsmonoamine oxidase inhibitorsmonoaminergic dysfunctionmotivational deficitsselegilinetreatment-resistant depression

Identifiers

PMID41304909
PMCPMC12655414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.